DDIT3 and diffuse large B-cell lymphoma: In cases of DLBCL non‐responding to RIS and rituximab, as well as “non‐DLBCL” monomorphic PTLD and primary CNS‐lymphoma, polychemotherapy is suggested, mostly consisting of R‐CHOP, CHOP, and COP regimens.35, 62